reports
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferenc...
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences: 1x1s around J.P. Morgan Healthcare Conference San Francisco, U...
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Busin...
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster session at ASN kidney week, the world’s premier nephrology meeting Successful completion of private placement supported by ex...
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Ope...
Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025 Halle (Saale) / Munich, Germany, November 25, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 3...
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomar...
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meetingVIVIAD analyses continue to support varoglutamstat’s potential in kidney disease, and consistently provide further evidence for a beneficial impact on kidney function based on...
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of Nephrology (ASN) Kidney Week 2025Date: November 5 –...
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Ra...
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTIO...
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Busin...
Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Compelling kidney function data and meta-analysis from two Phase 2 studies, VIVIAD and VIVA-MIND, presented in oral presentation at ERA 2025 Expanded IP portfolio including novel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for patent term extensionPre-clinical data showing strong additive and synergistic ...
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Ope...
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025 Halle (Saale) / Munich, Germany, August 27, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its half year financial results for the period ended June 30, 2025 a...
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12:00 pm CES...
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meet...
Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting Vivoryon Therapeutics N.V. Reports Outcomeof 2025 Annual General Meeting Halle (Saale) / Munich, Germany, June 24, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on diabetic kidney disease, held its Annual General Meeting (AGM) today at 1:00 p.m. (CEST). The shareholders approved all items on the agenda of the meeting, including the appointment of Dr. Julia ...
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational P...
Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimensNovel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity for pate...
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Ope...
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle (Saale) / Munich, Germany, June 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its first quarter financial results for the period ended March 31, 2025 and pr...
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and V...
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025 Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congres...
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio wit...
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity through 2044 with subsequent opportunity for patent term extensionNew U.S. patent granted after accelerated examination process covers the active polymorph of varoglutamstat, Vivoryon’s lead drug in development Additional patents for medical use and dosing regimen...
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on ...
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025 Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meetingon June 24, 2025 Halle (Saale) / Munich, Germany, May 13, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its 2025 Annual General Meeting will be held on Tuesday, June 24, 2025 at 01:00 p.m. (CEST) at the Amsterdam off...
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results an...
Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney diseaseVaroglutamstat Phase 2 program shows highly consistent, statistically significant and clinically meaningful improvement of kidney function (eGFR) versus placebo in two independent randomized double-blind placebo-controlled studiesStatistical evidence from meta-analysis of VIVIAD and VIVA-...
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 ...
Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million Vivoryon Therapeutics N.V. Signs Financing Agreementfor up to EUR 15 Million Halle (Saale) / Munich, Germany, April 24, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (“Vivoryon” or the “Company”), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it has entered into a Standby Equity Purchase Agreement (“SEPA”) of up to EUR 15 million, with Yorkvill...
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results ...
Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Vivoryon Therapeutics N.V. to Report Full Year 2024 Financial Results and Operational Progress on April 29, 2025 Halle (Saale) / Munich, Germany, April 17, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that it will publish its financial results for the full ...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update w...
Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers Halle (Saale) / Munich, Germany, February 19, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced key takeaways from its virtual R&D update with KOL (Key Opinion Leader) speakers held February 18, 2025. ...
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speaker...
Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Vivoryon Therapeutics N.V. to Host Virtual R&D Update with KOL Speakers on February 18, 2025 Halle (Saale) / Munich, Germany, February 11, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced to host a virtual R&D update with KOL (Key Opinion Leader) speakers on February 18, 2025. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.